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Abstract Two novel oral drugs that target androgen
signaling have recently become available for the treatment
of metastatic castration-resistant prostate cancer (mCRPC).
Abiraterone acetate inhibits the synthesis of the natural
ligands of the androgen receptor, whereas enzalutamide
directly inhibits the androgen receptor by several mecha-
nisms. Abiraterone acetate and enzalutamide appear to be
equally effective for patients with mCRPC pre- and
postchemotherapy. Rational decision making for either one
of these drugs is therefore potentially driven by individual
patient characteristics. In this review, an overview of the
pharmacokinetic characteristics is given for both drugs and
potential and proven drug–drug interactions are presented.
Additionally, the effect of patient-related factors on drug
disposition are summarized and the limited data on the
exposure–response relationships are described. The most
important pharmacological feature of enzalutamide that
needs to be recognized is its capacity to induce several key
enzymes in drug metabolism. The potency to cause drug–
drug interactions needs to be addressed in patients who are
treated with multiple drugs simultaneously. Abiraterone
has a much smaller drug–drug interaction potential;
however, it is poorly absorbed, which is affected by food
intake, and a large interpatient variability in drug exposure
is observed. Dose reductions of abiraterone or, alterna-
tively, the selection of enzalutamide, should be considered
in patients with hepatic dysfunction. Understanding the
pharmacological characteristics and challenges of both
drugs could facilitate decision making for either one of the
drugs.
Key Points
Understanding the pharmacology of abiraterone and
enzalutamide could facilitate rational therapeutic
decision making for either one of the drugs based on
patient-specific factors.
Abiraterone bioavailability is low and is majorly
affected by food intake.
Enzalutamide affects the activity of multiple hepatic
enzymes and is therefore prone to cause drug
interactions.
1 Introduction
Prostate cancer is the second most commonly diagnosed
cancer in men and one of the most common causes of death
related to cancer in men [1]. After primary treatment with
chemical or surgical castration, most patients progress to a
state of the disease termed metastatic castration-resistant
prostate cancer (mCRPC), with a median survival
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of \2 years [2]. Until recently, only docetaxel
chemotherapy provided prolongation of survival in this
stage of the disease [3]. The understanding of the
remaining dependency of prostate cancer on the androgen
receptor pathway was an incentive to develop targeted
therapies for extra-gonadal androgen signaling [4–6]. Two
novel oral androgen receptor targeted drugs, abiraterone
acetate and enzalutamide, have recently become available
and can substantially prolong survival [5, 7–10].
Abiraterone acetate (Zytiga), a prodrug of abiraterone,
is a selective and irreversible blocker of the cytochrome
P450 (CYP) C17 enzyme (CYP17), a crucial enzyme in
testosterone and estrogen synthesis, resulting in virtually
undetectable serum and intratumoral androgen levels [11,
12]. Abiraterone acetate is registered in combination with
low-dose prednisolone because the inhibition of CYP17
decreases the production of endogenous glucocorticoids.
Enzalutamide (Xtandi) is a potent androgen signaling
receptor inhibitor and acts in multiple ways on the andro-
gen pathway. Enzalutamide (1) competitively inhibits the
binding of androgen to the androgen receptor; (2) inhibits
nuclear translocation and recruitment of cofactors; and (3)
inhibits the association of the activated androgen receptor
with DNA [6]. The active metabolite N-desmethyl enza-
lutamide is equipotent to the parent compound in vitro, and
is present in plasma at the same concentration level as
enzalutamide, which may add to the antitumor activity of
enzalutamide in patients treated with this drug [13].
Both of these novel drugs are administered orally once
daily in a fixed dose, are well tolerated [14, 15], and appear
to be equipotent in the pre- and postchemotherapy setting
[7–10, 16]. Since these drugs show comparable efficacy,
other characteristics might drive rational therapeutic deci-
sion making. A better understanding of the pharmacology
of these drugs in relation to awareness of patient-specific
conditions (e.g. comedication, comorbidities) could facili-
tate the choice for either one of these drugs.
The aim of this review is to give an overview of the
pharmacokinetic characteristics of abiraterone acetate and
enzalutamide. Moreover, results from additional studies on
potential drug–drug interactions, the involvement of drug
transporters, and data on the exposure–response relation-
ship have been incorporated in this overview. Finally, the
effect of specific patient characteristics on drug disposition
will be discussed.
2 Search Strategy
PubMed and EMBASE searches were performed using the
following search terms: ‘Abiraterone OR Zytiga OR abi-
raterone acetate OR CB7630’ OR ‘Enzalutamide OR
MDV3100 OR Xtandi OR N-desmethylenzalutamide’ in
combination with ‘Excretion’ OR ‘Distribution’ OR ‘Ab-
sorption’ OR ‘Bioavailability’ OR ‘availability’ OR
‘pharmacokinetics’ OR ‘metabolism’ OR ‘biotransforma-
tion’ OR ‘cytochrome p450 enzyme’ OR ‘drug–drug
interaction’ OR ‘transporter’. In addition, citation snow-
balling was used to find other relevant studies. Registration
information from the European Medicines Agency (EMA)
and the US FDA was used, and results reported in Clini-
calTrials.gov were screened. Results were limited to stud-
ies in humans and English language full-text articles
published until 22 February 2016.
Our search revealed 491 hits: 142 articles did not con-
tain pharmacokinetic data, 170 articles were reviews that
did not obtain original data, 18 articles were not accessible
through our library, 35 articles were not in English, 40
articles described data not in humans, 39 articles repre-
sented expert opinions, letters, and editorials, and 25 arti-
cles did not contain data on abiraterone acetate and
enzalutamide. The remaining 22 original articles regarding
the pharmacokinetics of enzalutamide and abiraterone were
included in this study. For both drugs, the most recent drug
label of the EMA and FDA was included.
An overview of the pharmacokinetic properties of abi-
raterone, enzalutamide and N-desmethyl enzalutamide is
presented in Table 1, while Table 2 describes the effect of
renal and hepatic impairment. Table 3 shows an overview of
hepatic enzymes that are involved in the metabolism of abi-
raterone and enzalutamide, as well as hepatic enzymes that are
inhibited or induced by these drugs. Tables 4 and 5 summarize
drug–drug interactions, and Table 6 shows examples of fre-
quently used drugs that are potentially affected by enzalu-
tamide and abiraterone. Figures 1 and 2 show the metabolism
of abiraterone acetate and enzalutamide, respectively.
3 Abiraterone Acetate
3.1 Absorption
The prodrug abiraterone acetate is rapidly hydrolyzed into
abiraterone in vivo. No abiraterone acetate could be
detected in plasma in patients treated with abiraterone
acetate [12]; therefore, only abiraterone will be responsible
for the clinical activity. After a median of 2 h, the maxi-
mum plasma concentration (Cmax) of abiraterone was
achieved (Table 1) [17]. Abiraterone acetate is classified as
a Biopharmaceutics Classification System (BCS) class IV
drug due to its low solubility and low permeability char-
acteristics. The solubility of abiraterone acetate rapidly
declines at pH[1 [17]. The absolute bioavailability of this
agent has not been studied; however, results from the mass
balance study after intake of abiraterone acetate on an
empty stomach suggest that bioavailability can be 50 % at
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Table 1 Pharmacokinetic parameters
F [%] Protein
binding
[%]
tmax
[h]
t [h] AUC [ng h/mL]
(CV %)
Vd/F
(L)
CL/F [L/h]
(CV %)
Ctrough
[ng/mL]
Cmax
[ng/mL]
References
Abiraterone NA *99.8 2 24 993a (64) 5620 1198 (65) 11.1 226 [4, 17, 20]
Enzalutamide NA *98 1–2 5.8 days 322,000a (26.6) 110 0.55 (18) 11,400 16,600 [13, 15,
20, 31]
N-desmethyl
enzalutamide
NA *95 4 7.8 days 278,000a (30.7) NA NA 13,000 12,700 [13, 15,
20, 31]
F absolute bioavailability, tmax median time to peak concentration, t mean elimination half-life, AUC mean area under the concentration–time
curve from time zero to 24 h, Vd/F mean apparent volume of distribution, CL/F apparent oral clearance, Ctrough mean minimum concentration,
Cmax mean maximum concentration, NA not available, CV % percentage coefficient of variation
a AUC24 for abiraterone and AUCtau for enzalutamide
Table 2 Effect of renal and hepatic impairment on the pharmacokinetics of abiraterone acetate and enzalutamide
Hepatic impairment Renal impairment References
Mild Moderate Severe Mild Moderate Severe
Abiraterone AUCinf
increased
(111)a
AUCinf
increased
(357)a
DN AUCInf
increased (614)*,a
NAb NAb AUCinf no
changec
[14, 21]
Enzalutamide and
N-desmethyl enzalutamide
AUCinf
increased
(14 %)
AUCinf
increased
(14 %)
AUCinf increased
(34 %)
No
changed
No
changed
NA [15, 20,
31]
AUCinf area under the concentration–time curve from time zero to infinity, DN dose normalized, NA not available
* Dose normalized; in this study, patients with severe liver impairment received 1/16th of the dose of healthy volunteers: 125 vs. 2000 mg of a
suspension
a Estimated geomatric mean ratios
b Not studied since patients with severe renal impairment did not show exposure more than twice the normal exposure
c End-stage renal disease patients who required hemodialysis
d Calculated in a post hoc population pharmacokinetic analysis
Table 3 Enzymes and transporters involved in pharmacokinetics
Substrate of: Effector of: References
Enzyme phase I Enzyme phase II Inhibitor Inducer
Abiraterone CYP3A4 (minor) SULT2A1 (major) CYP2D6 (strong)
CYP2C8 (moderate)
CYP1A2 (weak)
[14, 18, 22]
Enzalutamide CYP2C8
CYP3A4/5
CYP2C8 (weak)
P-gp (in vitro)
CYP3A4 (strong)
CYP2C19(moderate)
CYP2C9 (moderate)
CYP2D6 (moderate)
CYP1A2 (weak)
[30, 32]
N-desmethyl enzalutamide CYP2C8
CYP3A4
Unknown Unknown Unknown [32]
CYP cytochrome P450, SULT2A1 sulfotransferase 2A1, P-gp P-glycoprotein
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its maximum since unchanged abiraterone acetate
accounted for 50 % of the drug recovered in feces [18].
In a relative bioavailability study, a formulation of
abiraterone acetate in olive oil increased exposure 4.5-fold
compared with the tablet formulation, indicating that a
fatty environment significantly improves bioavailability
[17]. These findings support the major food effect on abi-
raterone exposure. In a single-dose study of abiraterone in
healthy volunteers, the area under the plasma concentra-
tion–time curve (AUC) and Cmax increased 10- and 17-fold
after a high-fat meal, respectively, and sevenfold and
fivefold after a low-fat meal compared with intake without
food, respectively [17]. In cancer patients, a 4.4-fold
increase in AUC was observed after intake of abiraterone
acetate with a high-fat meal compared with fasted condi-
tions; in this study, a capsule was used instead of the
currently registered tablets, which may have affected the
outcome [4]. However, in a more recent study in cancer
patients, only a twofold increase in exposure was observed
with a high-fat meal compared with modified fasting [19].
The origin of this difference in food effect between patients
and healthy volunteers is as yet unclear.
Some of the observed large increases in abiraterone
exposure with food versus intake on an empty stomach
seem to contradict data from the mass balance study.
Differences in patient populations, analytical techniques,
drug formulation, and types of meals may all contribute to
these paradoxical observations.
It is recommended that abiraterone acetate be taken
in fasting conditions [14]. A plausible reason for this
recommendation is that the composition of meals (espe-
cially the fat content) can vary, and this will substantially
affect abiraterone exposure.
3.2 Distribution
Abiraterone is highly protein bound to both albumin
(95.6–99.9 %) and a1-glycoprotein (89.4–95.6 %). It is
extensively distributed in tissue, with an apparent central
volume of distribution (Vd) of 5630 L [14]. The ratio of
whole blood to plasma concentrations of abiraterone was
0.523, which indicates no substantial binding to red blood
cells. This observation is supported by in vitro data
showing that radioactivity of abiraterone and metabolites
was limited to the plasma component of the blood [18].
Animal studies showed that abiraterone passes the blood–
brain barrier, however this has not been explored in
humans [20].
3.3 Metabolism
The prodrug abiraterone acetate is readily converted to
abiraterone through hydrolysis; the esterases involved
herein are not yet identified [18]. Thereafter, abiraterone is
extensively metabolized through several pathways, pri-
marily by sulfotransferase 2A1 (SULT2A1) to abiraterone
sulphate (M45), and by SULT2A1 and CYP3A4 to N-oxide
abiraterone sulphate (M31) [Fig. 1] [17, 18]. M45 and M31
are the major inactive metabolites and both are responsible
for[40 % of drug present in the plasma [18].
Table 4 Drugs that interact with abiraterone or enzalutamide
Inducing
drug
Inhibitory
drug
Effects observed Authors’ recommendations References
Abiraterone Rifampicin AUCinf decreased
(45 %)
Avoid combination if possible
If not possible, the dose of abiraterone
acetate should be increased to 1000 mg
bid
[14, 22,
25]
Ketoconazole AUCinf increased
(15 %)
Not clinically relevant [14, 22,
25]
Enzalutamide ? N-desmethyl
enzalutamide
Rifampicin AUCinf decreased
(37 %)
Switch to alternatives that are not
inducers of CYP3A4
If not possible, the dose of enzalutamide
should be increased to 240 mg once
daily
[15, 20]
Itraconazole AUCinf increased
(1.3-fold)
Not clinically relevant [15, 20,
32]
Gemfibrozil AUCinf increased
(2.2-fold)
Switch to alternatives that are not
inhibitors of CYP2C8
If not possible, the dose of enzalutamide
should be reduced to 80 mg once daily
[15, 20,
32]
AUCinf area under the concentration–time curve from time zero to infinity, bid twice daily
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3.4 Excretion
Abiraterone acetate is primarily excreted in feces. No
unchanged abiraterone acetate or abiraterone could be
detected in urine, and only approximately 5 % of abi-
raterone metabolites were recovered in urine, of which 4 %
were N-oxide abiraterone sulphate (M45) [18]. In patients
undergoing hemodialysis, the exposure of abiraterone was
comparable to that of patients with normal renal function,
underscoring the minor involvement of the renal elimination
pathway [21]; therefore, no dose adjustments are indicated,
which is in accordance with the label (Table 2) [14, 22].
Since abiraterone is extensively metabolized by the
liver, an effect of hepatic impairment on abiraterone
pharmacokinetics is expected. In patients with moderate
hepatic impairment (Child–Pugh B), the exposure
increased fourfold. In severe hepatic impairment (Child–
Pugh C) a 16-fold reduced dose resulted in a decreased
Table 5 Effect of abiraterone and enzalutamide on coadministrated drugs
Drugs Enzyme Effects
observed
Authors’ recommendations References
Abiraterone
Acetate
Dextromethorphan CYP2D6 AUC24
increased
(2.9-fold)
If possible, switch to alternatives that are not metabolized through
CYP2D6
Be aware that substrates of CYP2D6 are presumably more active.
Be aware of side effects and toxicity. Consider dose reduction of
concomitant CYP2D6 substrate with at least twofold
Avoid use of CYP2D6 substrates with a narrow therapeutic index
[14, 22,
26]
Theophylline CYP1A2 No effect Not clinically relevant: no change in medication is required [14, 22,
26]
Pioglitazone CYP2C8 AUC24
increased
(46 %)
If possible, switch to alternatives that are not metabolized
through CYP2C8
Be aware that substrates of CYP2C8 are presumably more
active. Be aware of side effects and toxicity
Avoid use of CYP2C8 substrates with a narrow therapeutic
index
[14, 22]
Enzalutamide Pioglitazone CYP2C8 AUCinf
increased
(20 %)
Not clinically relevant: no change in medication is required [15, 20,
32]
S-Warfarin CYP2C9 AUCinf
decreased
(56 %)
If possible, switch to alternatives that are not metabolized
through CYP2C9
Be aware that substrates of CYP2C9 are presumably less active
and elevate the dose based on efficacy
Avoid use of CYP2C9 substrates with a narrow therapeutic
index
[15, 20,
32]
Omeprazole CYP2C19 AUCinf
decreased
(70 %)
If possible, switch to alternatives that are not metabolized
through CYP2C19
Be aware that substrates of CYP2C19 are less active and
elevate the dose based on efficacy
Avoid use of CYP2C19 substrates with a narrow therapeutic
index
[15, 20,
32]
Midazolam CYP3A4 AUCinf
decreased
(86 %)
If possible, switch to alternatives that are not metabolized
through CYP3A4
Be aware that substrates of CYP3A4 are substantially less
active. The dose of CYP3A4 substrates should be adjusted to
achieve comparable efficacy
Avoid use of CYP3A4 substrates
[15, 20,
32]
Dextromethorphan CYP2D6 AUCinf
decreased
(31 %)
Be aware that substrates of CYP2D6 are moderately less active
Avoid concomitant use of CYP2D6 substrates with a narrow
therapeutic index
[15, 20]
Caffeine CYP1A2 AUCinf
decreased
(11 %)
Not clinically relevant: no change in medication is required [15, 20]
CYP cytochrome P450, AUC24 area under the concentration–time curve from time zero to 24 h
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exposure of only 56 % compared with healthy controls.
The dose-normalized AUC was increased approximately
sevenfold in severe hepatic impaired patients compared
with healthy controls [21].
Hepatic impairment decreases the elimination of abi-
raterone, resulting in an increase in elimination half-life of
4.6–5.5 h for patients with mild/moderate liver impairment
(Child–Pugh A/B) (Table 2) [21]. Remarkably, in patients
with severe hepatic impairment (Child–Pugh C), the half-
life only increased by 3.2 h [21].
Abiraterone is contraindicated in patients with severe
hepatic impairment [21]. For patients with moderate hep-
atic impairment, for whom alternative treatments are not an
option, a starting dose of 250 mg could be considered.
Table 6 Examples of drugs subject to drug–drug interactions with enzalutamide and abiraterone
Substrates Examples of potentially affected drugs Expected effect of
enzalutamide
Expected effect of
abiraterone
References
CYP1A2
substrates
Duloxetine, clozapine No relevant effect No relevant effect [24]
CYP2C8
substrate
Repaglinide No relevant effect AUC increase [24]
CYP2C9
substrates
Warfarin, acenocoumarol, losartan, diclofenac, tolbutamide AUC decrease NA [24]
CYP2C19
substrates
Omeprazole, esomeprazole, clopidogrel, citalopram, diazepam AUC decrease NA [24]
CYP2D6
substrates
Oxycodone (into highly active metabolite), metoprolol, haloperidol,
flecainide, paroxetine
AUC decrease AUC increase [24]
CYP3A4
substrates
Oxycodone (into less active metabolite), methadone, ticagrelor,
simvastatin, nifedipine, fentanyl, St John’s Wort
AUC decrease NA [24]
The presented list of examples is not inexhaustive, and the extent of the effect on the probe substrate is described in Table 4
CYP cytochrome P450, AUC area under the concentration–time curve, NA not available
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Fig. 1 Abiraterone acetate metabolism. The prodrug abiraterone
acetate is readily converted to abiraterone through hydrolysis.
Thereafter, abiraterone is extensively metabolized through several
pathways, primarily by SULT2A1 to abiraterone sulphate, and by
SULT2A1 and CYP3A4 to n-oxide abiraterone sulphate. SULT2A1
sulfotransferase 2A1, CYP cytochrome P450
1374 G. E. Benoist et al.
Further dose individualization in this group of patients
could be driven by either the side effects or therapeutic
drug monitoring of abiraterone.
Something to be aware of is that abiraterone itself can
cause elevated liver function tests (ALT, AST, bilirubin) [22].
3.5 Drug–Drug Interactions
Abiraterone is a substrate of SULT2A1 and CYP3A4
(Table 3). Concomitant administration with rifampicin, a
strong inducer of CYP3A4 enzymes as well as sulfation
enzymes, decreased exposure to abiraterone by 55 % [23–
25], while ketoconazole, a strong CYP3A4 inhibitor,
increased exposure to abiraterone by only 15 %, which was
not considered clinically relevant (Table 4) [25]. This
discrepancy could be explained by the major role of
SULT2A1 in the metabolism of abiraterone. The EMA and
FDA accepted different labeling recommendations
regarding coadministration of abiraterone with substrates
of CYP3A4. Both agencies advise avoiding coadministra-
tion of abiraterone with strong CYP3A4 inducers. In case
avoidance is not possible, the US label also advises
increasing the dosing frequency to twice daily when
coadministered with a CYP3A4 inducer. Although this is
not based on clinical data (Table 4) [14, 22], in our opinion
the dose should be elevated when abiraterone acetate is
used together with strong CYP3A4 inducers. Measurement
of drug concentrations of abiraterone could support the
clinician in these situations.
In vitro studies indicated that abiraterone is a strong
inhibitor of CYP2D6 and CYP1A2, and a moderate inhi-
bitor of CYP3A4, CYP2C9, and CYP2C19 [17]; no further
in vivo drug interaction studies were conducted for the
CYP3A4, CYP2C9, and CYP2C19 substrates. A study in
patients treated with abiraterone acetate showed a 2.9-fold
higher exposure to the CYP2D6 substrate dextromethor-
phan, confirming that abiraterone is a strong CYP2D6
inhibitor; however, coadministration of the CYP1A2 sub-
strate theophylline with abiraterone did not alter theo-
phylline exposure [26]. Finally coadministration with the
CYP2C8 substrate pioglitazone increased pioglitazone
exposure by 46 % [14, 22]. Based on these data, coad-
ministration of abiraterone with CYP2D6 substrates should
be avoided when possible. If treatment with the CYP2D6
substrate cannot be interrupted, the dose should be reduced
on forehand for substrates with a narrow therapeutic index.
Careful monitoring of side effects is advised for drugs with
a broader therapeutic index [14, 22]. Since the effect of
abiraterone on CYP2C8 is more modest, only coadminis-
tered CYP2C8 substrates with a narrow therapeutic index
should be monitored more closely and dose adjusted
accordingly (Table 5) [14, 22]. Examples of drugs that are
potentially subject to drug–drug interactions with abi-
raterone are described in Table 6.
N
N
N
O
NH
F
S
O
CH3
FF
F
CH3
CH3
N
N
N
O
OH
F
S
O
FF
F
CH3CH3
N
N
N
O
NH
F
S
O
FF
F
CH3CH3 OH
N
N
N
O
NH2
F
S
O
FF
F
CH3CH3
CYP2C8, CYP3A4
CYP2C8?, CYP3A4?
N-desmethyl enzalutamide(M2)
Metabolite M6
Carboxyl metabolite enzalutamide (M1)
Enzalutamide
Fig. 2 Enzalutamide metabolism. The proposed pathway to form N-
desmethyl enzalutamide is via M6 and M1 through CYP2C8 and
CYP3A4 metabolism. N-desmethyl enzalutamide is metabolized by
carboxylesterase 1 to the carboxyl metabolite; no CYP enzymes
involvement in further metabolism were identified. CYP cytochrome
P450
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Acid-reducing agents may affect abiraterone exposure
since the solubility of abiraterone acetate decreased rapidly
as pH increases [1 [17]. No formal interaction studies
have been conducted to investigate the effect of acid-re-
ducing agents on abiraterone exposure.
3.6 Transporters
In vitro studies show that abiraterone acetate and abi-
raterone are not substrates for the efflux transporter
P-glycoprotein (P-gp) [17]. Additionally, abiraterone
showed little inhibitory effect on P-gp [17]; therefore no
clinically relevant interactions with P-gp substrates are
expected. The two major metabolites abiraterone sulphate
and N-oxide abiraterone sulphate showed in vitro inhibi-
tion of the hepatic uptake transporter organic anion trans-
porting polypeptide B1 (OATP1B1) [27], which could
imply potential interactions with drugs that are OATP
substrates (Table 6); however, no information is available
to confirm drug–drug interactions attributable to the inhi-
bition or induction of transporters [14].
3.7 Patient Characteristics
No formal studies have been conducted to assess the
influence of age, weight, height, or genetic polymorphisms
on drug exposure and treatment response [17]; however, in
a post hoc population pharmacokinetic analysis, concomi-
tant food intake, and mild and moderate liver impairment
were identified as relevant covariates that affect abiraterone
exposure [28]. Other covariates (age, testosterone, body
mass index, and total plasma protein) showed no significant
effect on abiraterone exposure [28]. Ethnicity (Asian vs.
Caucasian) does not appear to affect the pharmacokinetics
of abiraterone [29].
3.8 Exposure–Effect Relationships
An association was shown between trough abiraterone con-
centrations and decreased Prostate Specific Antigen (PSA)
and increased survival [14]. Large interpatient variability in
abiraterone exposure was observed (40.5–140.6 %) [14];
therefore, hypothetically, a subgroup of patients will be
undertreated at the normal dose of 1000 mg once daily, and
monitoring of Ctrough levels of abiraterone may be a tool for
identifying this subgroup of patients. A better understanding
of abiraterone pharmacokinetics might help to optimize the
dose of the individual patient. For example, knowledge of the
food effect in patients, the impact of dose increases in
patients with suboptimal exposure, as well as the effect of
patient characteristics on the pharmacokinetics of abi-
raterone should be studied since patients in clinical trials are
rather homogeneous due to strict exclusion criteria.
4 Enzalutamide
4.1 Absorption
Enzalutamide is rapidly absorbed, with a Cmax reached
after 1–2 h (Table 1) [30]. N-desmethyl enzalutamide (M2)
and the carboxylic enzalutamide (M1) are formed slowly,
with a median Cmax in plasma reached after 132 and 96 h,
respectively [30]. For enzalutamide, the absolute
bioavailability is unknown since no intravenous formula-
tion of this agent is available; however, based on data from
the mass balance study, approximately 84 % of enzalu-
tamide appears to be absorbed after oral administration
[30]. In order to improve the solubility of this BCS class II
substance (indicating high permeability and low solubility),
the formulation of a soft capsule with enzalutamide dis-
solved in caprylocaproyl macrogolglycerides (CCMG) was
developed [20]. A moderate food effect was observed on
the rate of enzalutamide absorption but not on the extent of
absorption [30]. Dose-proportional pharmacokinetics were
observed from 40 to 360 mg [15].
4.2 Distribution
Enzalutamide is extensively distributed into tissues and is
highly protein bound (approximately 97–98 %), which
results in an apparent oral distribution volume (Vd/F) of
approximately 110 L [20]. The active metabolite N-des-
methyl enzalutamide is equally protein bound (95 %) [20].
In the mass balance and biotransformation study, the
overall whole blood to plasma ratio was 0.55, which
indicates little binding or distribution to red blood cells
[30]. Partitioning to the brain was evaluated in rats [31],
and penetration in human brain tissue still needs to be
explored.
4.3 Metabolism
As confirmed in a drug interaction study, in vitro studies
indicated that enzalutamide is mainly metabolized by
CYP2C8, with minor CYP3A4/5 involvement [32]. In a
14C-enzalutamide mass balance study, a total of seven
metabolites were identified [13]. The two main metabolites
in circulation are the active N-desmethyl enzalutamide
(M2), which in vitro is equally active as enzalutamide, and
the inactive carboxylic acid metabolite (M1) (Fig. 2) [15,
20]. The mean steady-state Ctrough concentrations are
similar for enzalutamide and its active metabolite N-des-
methyl enzalutamide, and therefore both substances con-
tribute to pharmacological activity. The inactive carboxylic
metabolite accounts for approximately 75 % of the expo-
sure [15, 20]. The proposed pathway to form M2 is via M6
and M1, through CYP2C8 and CYP3A4 metabolism
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(Fig. 2) [32]. N-desmethyl enzalutamide (M2) is metabo-
lized by carboxylesterase 1 to the carboxyl metabolite
(M1). No CYP enzymes involved in further metabolism
were identified [13].
4.4 Excretion
Renal elimination is the major route of excretion. Seventy-
one percent of the total dose was recovered in urine, pri-
marily as the carboxyl metabolite (approximately 63 %),
and only a trace amount of unchanged parent and
metabolites were found in urine and feces [13]. In a
post hoc population pharmacokinetic analysis based on
pre-existing renal function, no difference in clearance for
mild and moderate renal impairment was observed [13]
(Table 2). No data are available on pharmacokinetic
changes in patients with severe renal impairment.
The influence of mild, moderate, and severe hepatic
impairment was evaluated. Enzalutamide and N-desmethyl
enzalutamide exposure increased approximately 14 % in
patients with mild (Child–Pugh A) and moderate (Child–
Pugh B) liver impairment [30], while in severe hepatic
impairment (Child–Pugh C), exposure increased 34 %.
Nevertheless, in patients with severe hepatic impairment,
the elimination half-life of enzalutamide was increased
twofold [30]. Considering the marginal effect on exposure,
an adjusted starting dose is not required in patients with
mild/moderate hepatic impairment (Table 2) [15, 20, 30].
4.5 Drug–Drug Interactions
As mentioned previously, enzalutamide is primarily
metabolized by CYP2C8 and also, to a lesser extent,
CYP3A4 (Table 3). Therefore, an interaction study was
conducted to investigate the effect of gemfibrozil, a strong
CYP2C8 inhibitor, on the sum exposure of enzalutamide
and N-desmethyl enzalutamide, which increased 2.2-fold
[32]. The strong CYP3A4 inhibitor itraconazole increased
the sum exposure 1.3-fold [32]. An interaction study with
the inducer rifampin showed that exposure to enzalu-
tamide decreased by 66 %, and exposure to N-desmethyl
enzalutamide increased 15 %. Consequently, the sum
exposure decreased only 37 %, which could be explained
by the major effect of rifampicin on enzalutamide meta-
bolism (CYP3A4 and CYP2C8), with only limited effect
on N-desmethyl enzalutamide, which is mainly metabo-
lized by carboxylesterase [15, 20] (Fig. 1) [ClinicalTri-
als.gov identifier NCT02138799). Table 4 provides a
summary of drug–drug interactions that affect enzalu-
tamide exposure.
Enzalutamide strongly induces CYP3A4 and moderately
induces CYP2C19 and CYP2C9. A decrease in exposure of
86, 70, and 56 %, respectively, was observed for the
CYP3A4 substrate midazolam, the CYP2C19 substrate
omeprazole, and the CYP2C9 substrate S-warfarin when
coadministered with enzalutamide [32]. The drug label
warns for coadministration of drugs that are substrates of
these enzymes, with a narrow therapeutic index [20]. In
contrary to the in vitro observation, the induction of
CYP2C8 was deemed not clinically significant when the
effect of enzalutamide on pioglitazone exposure, a
CYP2C8 substrate, was evaluated [32]. Gibbons et al.
reported that the pregnane X receptor (PXR) might also be
involved as exposure to the hydroxyl metabolites of the
tested substrates decreased while elevated exposures were
expected. Induction of the UDP glucuronosyltransferase 1
polypeptide A1 (UGT1A1) via PXR might explain this
phenomenon since many metabolites are glucuronidated
via UGT1A1 [32].
Finally, in vitro studies suggested that enzalutamide is
an inhibitor of CYP2B6, CYP1A2, and CYP2D6 [20].
Unexpectedly, in a clinical study with CYP1A2 and
CYP2D6 probes, the exposure of the CYP1A2 substrate
caffeine was reduced by 11 %. Exposure of dex-
tromethorphan, a CYP2D6 substrate, was also reduced by
31 % due to enzalutamide coadministration. In this study,
the metabolites of dextromethorphan were elevated. It was
suggested that the induction of CYP3A4 and UGT might
contribute to the reduced exposure of dextromethorphan
(ClinicalTrials.gov identifier NCT02225093). An addi-
tional explanation is that enzalutamide is not a CYP2D6 (or
CYP1A2) inhibitor in vivo, but a weak CYP2D6 inducer.
Lastly, no data are available on the effect of enzalutamide
on CYP2B6 substrates in vivo. On the other hand, this
might be of less relevance considering the limited number
of CYP2B6 substrates used in clinical practice.
In conclusion, strong CYP2C8 inhibitors and strong
CYP3A4 inducers have a clinically relevant effect on
exposure of enzalutamide, and enzalutamide dose adjust-
ments are indicated when they are combined. The dosage
of enzalutamide should be reduced to 80 mg once daily in
combination with strong CYP2C8 inhibitors [15, 20]; in
combination with strong CYP3A4 inducers, the FDA and
EMA approved conflicting labeling. Both regulatory
authorities advise against the use of enzalutamide with
strong CYP3A inducers. In contrast to the EMA drug
label, the drug label approved by the FDA suggests dose
elevation to 240 mg once daily when avoidance is unde-
sirable, although this is not based on clinical data [15, 20].
In our opinion, it could be possible to combine enzalu-
tamide with strong CYP3A inducers when the dose of
enzalutamide is elevated to 240 mg once daily and drug
levels can be measured. In our opinion, drugs that are a
substrate of CYP3A4 should be avoided in combination
with enzalutamide. Concomitant use of drugs that are
substrate to CYP2C19, CYP2C9, or CYP2D6 might also
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require dose adjustments due to the gradual loss of effi-
cacy in combination with enzalutamide. In our opinion,
coadministered substrates of CYP2C19 and CYP2C9
should be avoided, especially when they have a narrow
therapeutic index. If dosing is necessary, awareness of this
phenomenon is warranted and doses of substrates should
be elevated based on efficacy. CYP2D6 substrates will be
moderately less active, and substrates with a narrow
therapeutic index should be avoided when possible
(Table 5). Examples of drugs that are potentially subject
to drug–drug interactions with enzalutamide are provided
in Table 6.
4.6 Transporters
Enzalutamide is not a substrate of P-gp or the breast
cancer resistance protein (BCRP). In in vitro experiments,
enzalutamide and N-desmethyl enzalutamide were shown
to be inhibitors of P-gp, and the carboxyl metabolite was
not an inhibitor or a substrate of P-gp [20]. In the drug–
drug interaction study, Gibbons et al. hypothesized that
the P-gp transporter may be induced via induction of
PXR, while in vitro studies do not support this hypothesis
[32]. Furthermore, inhibition of multidrug resistance-as-
sociated protein 2 (MRP2), BCRP and OATP1B1 could
not be excluded based on in vitro work [20]. The
emulsifier CCMG that is used to improve the bioavail-
ability of enzalutamide is known to inhibit P-gp in vitro
[20]. In the drug interaction trial of Gibbons et al., a
placebo with this emulsifier was used as a comparator,
therefore the effect of CCMG could not be determined
[20]. Thus far, no clinical studies have been conducted to
confirm transporter-mediated drug–drug interactions.
Nevertheless, the drug label approved by the EMA states
that drugs that are substrates of P-gp should be used with
caution [20].
4.7 Patient Characteristics
No formal study has yet been conducted to investigate the
influence of patient characteristics on exposure of enzalu-
tamide and N-desmethyl enzalutamide. For registration
purposes, a post hoc population pharmacokinetic analysis
(healthy volunteers and patients) was conducted in which
no significant influence of covariates was identified [13].
The effect of severe renal impairment on the pharma-
cokinetics of enzalutamide has not been studied. Caution
regarding the effects of the enzyme induction of enzalu-
tamide is especially warranted when coadministered with
antiepileptic drugs as this may result in lower pharma-
cokinetic exposure and loss of seizure control [13]. Eth-
nicity (Asian vs. Caucasian) does not appear to affect the
pharmacokinetics of enzalutamide [33].
4.8 Exposure–Response Relationships
Steady-state concentrations of enzalutamide are reached
after approximately 1 month. For enzalutamide, no expo-
sure–response relationship was identified for overall sur-
vival when administered at 160 mg. This was expected
since interpatient variability in enzalutamide and N-des-
methyl enzalutamide exposure (AUC, Cmin and Cmax) is
low (B30 %). In a retrospective analysis, efficacy was
similar in the four different exposure quartiles based on
steady-state Ctrough [13], which may imply that patients in
the lower quartile are treated equally effectively.
In a phase I study, more patients had seizures from dose
levels higher than 240 mg/day [5] Due to this finding and
the high incidence of grade 3 fatigue, the dose was lowered
before phase III trials started. In the phase III trials, patients
with a risk or history of seizures were excluded; however,
0.9 % of patients experienced seizures [16]. An analysis of
the association between exposure and new-onset seizures
was precluded by the low incidence of seizures in this
selected subgroup and the limited variability in the phar-
macokinetics of the drug. [13]. A postmarketing safety trial
was requested in order to assess the risk of seizure in
patients who were excluded from the randomized clinical
trial [13].
5 Conclusions
Both abiraterone and enzalutamide have pharmacokinetic
characteristics that need to be recognized in order to ade-
quately treat patients with mCRPC. Abiraterone is mod-
erately absorbed, and its bioavailability is majorly
increased by food, while enzalutamide is well absorbed and
has no food interference. Abiraterone is registered in
combination with low-dose prednisolone in order to over-
come side effects due to CYP17 blockade. Patients who
experience nausea around drug intake, or for whom fasting
around drug intake is difficult, might prefer treatment with
enzalutamide. Both drugs are primarily metabolized in the
liver, and the influence of mild, moderate, and severe liver
impairment has been described for the pharmacokinetics of
both drugs. Abiraterone requires dose reduction in patients
with impaired liver function, whereas no dose adjustment is
required for enzalutamide. Abiraterone is mainly excreted
in feces, while enzalutamide is predominantly excreted in
urine as inactive metabolite. Enzalutamide causes drug–
drug interactions since it induces several CYP enzymes for
which many potential coadministered drugs are substrates.
Caution should be taken when coadministering enzalu-
tamide with antiepileptic drugs as the pharmacokinetic
exposure of these drugs can be lowered by induction of
hepatic enzymes. In addition, in the phase III trial, seizures
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(0.9 %) were reported as an adverse event in a cohort of
patients without a known seizure disorder. Abiraterone has
a much smaller drug–drug interaction potential, and this
aspect should be considered in patients who are using
comedication. Furthermore, exposure–effect relationships
have been studied for both drugs. For abiraterone, an
exposure–efficacy relationship has been described.
A better understanding of the pharmacokinetics of abi-
raterone may facilitate dose optimization for the individual
patient which may beneficially affect treatment outcome.
For enzalutamide, no difference in efficacy was shown
across the concentration/exposure range when administered
at a single fixed dose of 160 mg daily, which may imply
that enzalutamide is administered at the higher end of the
exposure–response curve. These results warrant further
research in order to apply this knowledge for personalized
therapy in the future.
Both drugs appear to be equipotent in the treatment of
patients with mCRPC pre- and postchemotherapy. The
therapeutic choice might therefore be driven by patient-
specific features (e.g. comorbidities, comedication). This
review describes the presently available pharmacokinetic
data of abiraterone acetate and enzalutamide, and provides
an overview of the pharmacological aspects and challenges
involved in adequate treatment with these drugs.
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